Plandai Biotechnology Debt to Equity

As of the most recent data, PLPL shows a debt-to-equity ratio of -2.7. That is below the Healthcare sector average of 0.27. Scroll down for historical charts and peer comparison views.

The Healthcare sector average debt-to-equity ratio is about 0.27. Plandai Biotechnology is at -2.7, which is lower that average. That is roughly 1118.1% below the sector mean. Use the comparison chart on this page to see how PLPL stacks up against individual peers as well.

Investors watch PLPL's debt-to-equity ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Plandai Biotechnology's latest reading is -2.7. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.

Besides this debt-to-equity ratio page, Stockcircle has Plandai Biotechnology's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect debt-to-equity ratio (currently -2.7) with ownership activity and broader fundamentals.

The Healthcare average debt-to-equity ratio is about 0.27, while PLPL is at -2.7. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.